TFL Driven Urinary System Treatment Study

NCT ID: NCT06257368

Last Updated: 2024-02-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

373 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-07-24

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is:

To assess the use of Coloplast TFL Drive in daily practice

To confirm:

* the safety and efficacy of the Coloplast TFL Drive and its GUI (Graphical User Interface) with pre-embedded settings in Laser lithotripsy
* the safety and efficacy of the Coloplast TFL Drive and its GUI with pre-embedded settings for enucleation of prostate as treatment of benign prostate hyperplasia
* the safety and efficacy of the Coloplast TFL Drive and its GUI with pre-embedded settings for ablation of urological tumors

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urologic Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Coloplast TFL Drive

Thulium Fiber laser

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any adult patient, for which TFL laser is indicated for treating a urological disease (e.g. kidney or ureteral stones, urological tumor, BPH (Benign Prostate Hypertrophy…)

Exclusion Criteria

* Any condition when TFL laser should not be indicated as per the TFL user manual (untrained surgeon on laser use, patient's conditions)
* Patients with no signed consent form
* Patients \<18 years old
* Patients under tutorship or guardianship
* Patients who already took part in the study
* Pregnant or breastfeeding women
* Patient undergoing 2nd step laser procedure at inclusion
* Subject already included in another study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Coloplast A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Isabelle D de Berny

Role: STUDY_DIRECTOR

Coloplast Manufacturing France

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Bordeaux

Bordeaux, , France

Site Status RECRUITING

Clinique Jules Verne

Nantes, , France

Site Status RECRUITING

Hôpital Tenon

Paris, , France

Site Status RECRUITING

Hôpital Privé Francheville

Périgueux, , France

Site Status RECRUITING

HM Hospital Sanchinarro

Madrid, , Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jessica Heringer

Role: CONTACT

+33644287794

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Grégoire Robert, pr

Role: primary

Victor Tostivint, MD

Role: primary

Olivier Traxer, Pr

Role: primary

Richard Mallet, Dr

Role: primary

Javier Romero-Otero, Dr

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CP359

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.